TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04208178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib orally taken - continuous once daily, in a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib orally taken - continuous once daily, in a 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib matching Placebo
Description: Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
Study: NCT03895411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotalol
Description: Oral sotalol 2.5mg/kg/time, per 12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: Oral Propafenone 5mg/kg/time, pre 8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betaloc
Description: Oral betaloc 0.5mg/kg/time ,pre 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betaloc
Description: Oral betaloc 0.5mg/kg/time ,pre 12h
Study: NCT03320018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hydrogen
Description: Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Minocycline
Description: Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
Study: NCT04111068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS Active Stimulation
Description: a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS Active Stimulation
Description: a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS Sham/Placebo Stimulation
Description: The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS Sham/Placebo Stimulation
Description: The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
Study: NCT01699022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Cyclofem
Description: Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection.
Study: NCT01104194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids supplements (fish oil)
Description: 1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
Study: NCT00715650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits Counseling
Description: Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Orientation
Description: VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
Study: NCT04393298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginisortamab
Description: Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginisortamab
Description: Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginisortamab
Description: Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginisortamab
Description: Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Description: Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
Study: NCT00809692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: validated techniques for histamine response
Description: the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new technique for histamine response
Description: laser Dopper technique and genotyping
Study: NCT02643667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: -Ibrutinib will be supplied by Pharmacyclics Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: -Ibrutinib will be supplied by Pharmacyclics Inc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: -Standard of care
Study: NCT03268239

Intervention type: DEVICE
Group type: OTHER
Intervention: Additional MRI sequences
Description: Due to the participation in the study, the following sequences are added to the imaging protocol:~* 3D T1 GRE after injection (Gradient-Recalled Echo)~* 3D T1 TSE before injection (Turbo Spin Echo)~* 3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition.
Study: NCT01383889

Intervention type: OTHER
Group type: OTHER
Intervention: Physical exercise
Description: Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical exercise
Description: Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
Study: NCT04643925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle
Description: Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
Study: NCT01370512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg tablets by mouth three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 100 mg tablets by mouth three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: 60 mg tablets by mouth three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: 60 mg tablets by mouth three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: 60 mg tablets by mouth three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: 60 mg tablets by mouth three times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Looks exactly like the study drug but contains no active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Looks exactly like the study drug but contains no active ingredients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug but contains no active ingredients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug but contains no active ingredients
Study: NCT01757665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M
Description: Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
Study: NCT00261495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone HCl
Description: 8 to 32 mg once daily for 52 weeks (flexible dosing)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
Study: NCT03420924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal suit
Description: Forced-air warming device will be connected to the trouser legs of the thermal suit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hospital clothes
Description: The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
Study: NCT01153139

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)
Description: intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)
Description: intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
Study: NCT00429663

Intervention type: DEVICE
Group type: OTHER
Intervention: reamed, interlocking intramedullary nail
Description: Standard of care device for femur fracture repair

Intervention type: DEVICE
Group type: OTHER
Intervention: locking periarticular plate
Description: Standard of care device for femur fractures
Study: NCT02094443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 100 and 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 100 and 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT04204369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound education curriculum
Description: Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~* An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~* A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients.
Study: NCT00623389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IST (Implanted Stimulator-Telemeter)
Description: Pre-surgical exercise with surface electrical stimulation, surgery including electrode and IST- implanted pulse generator insertion, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
Study: NCT04256317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX030 (cedazuridine + azacitidine)
Description: Tablets/Capsules for oral administration
Study: NCT00152464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Oral drops Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
Study: NCT00508404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
Study: NCT04226222

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP-TDM FDG
Description: Semi-quantitative PET-TDM FDG Data and Texture Analysis
Study: NCT00640185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take up to two 40 mg tablets once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take one or two placebos once daily for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will take one or two placebos once daily for the duration of the study.
Study: NCT04256317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: Tablets for oral administration
Study: NCT04707937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online education
Description: Access to online modules about brachytherapy education in addition to receiving regular standard of care education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular standard of care education
Description: Access only to regular standard of care education
Study: NCT02173054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene gel with Eucerin
Description: Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene gel
Description: Adapalene gel: 2 fingertip unit to cover all over the face before going to bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene gel with placebo moisturizer
Description: Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
Study: NCT03662074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02781948

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Study: NCT00640185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will take one or two placebos once daily for the duration of the study.
Study: NCT02754102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Spray- Liquid (BAY987516)
Description: 50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
Study: NCT03542383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Definition Transcranial Direct Current Stimulation
Description: Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High Definition Transcranial Direct Current Stimulation
Description: Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
Study: NCT00872040

Intervention type: OTHER
Intervention: Ultrasound assessment of pelvic floor
Description: Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
Study: NCT02543255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate with prednisone
Description: Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone
Description: Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel with peg-filgrastim
Description: Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
Study: NCT03065296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musculoskeletal (MSK) Prescription Didactic Lectures
Description: In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musculoskeletal (MSK) home exercise hand-outs
Description: In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
Study: NCT00615732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Qigong
Description: 18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: 18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week